TD has acquired Cowen Inc. Please bookmark TD Securities for further updates.

Drug Pricing Survey

Insight by and

In contrast to investor fears, our survey respondents expect U.S. brand drug prices will continue to rise over the next 3 years, at a rate similar to the past. Biosimilar substitution could reach 25-30% of molecules where a biosimilar is available. Cholesterol, diabetes, hepatitis C, and oncology are likely to experience the greatest expected price erosion. Price controls still appear unlikely.

Survey Of Buyers Captured One-Fifth Of U.S. Retail Drug Purchases

Cowen and Company conducted its 24th Annual Drug Pricing/Purchasing Trends survey of U.S. drug buyers to gain insight into the direction of U.S. drug prices over the next 3 years. Our survey results are based on responses from 26 U.S. HMOs, PBMs and hospitals. Collectively, they purchased $42B+ of drugs in 2017, or about one-fifth of total U.S. retail drug purchases.

Continued Low-/Mid-Single Digit Rise In Brand Drug Acquisition Prices Projected

This year’s sample of purchasers anticipate that brand drug acquisition cost per unit will increase by 3-5% annually over the next three years. This is above last year’s 3-4% forecast. Thirteen percent of respondents attribute a substantial portion (75%) of the anticipated increase to higher-priced, newer therapies vs. 40% last year. Generic drug acquisition cost per unit is expected to increase by 1% over the next three years, versus last year’s 3% forecast.

Biosimilar Substitution Expectation Increased, Assuming A 30-40% Discount

Respondents indicate that an average of a 32% price discount would be needed to switch from a brand to a biosimilar product, while the weighted average is 39%. For molecules in which one biosimilar is available, an average of 30% of dispensed prescriptions are likely to be biosimilar substitutions in three years, while the weighted average is 25%. This rises to an average of 47% and weighted average of 46% when three biosimilars are available.

For more information, contact your Cowen sales representative.


Get the Full Report

If you’re already a member of our Research portal, log in.

Log In